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hen early prophase PtK
 
1
 
 or Indian muntjac cells
are exposed to topoisomerase II (topo II) inhibi-
tors that induce little if any DNA damage, they
are delayed from entering mitosis. We show that this delay
is overridden by inhibiting the p38, but not the ATM, kinase.
Treating early prophase cells with hyperosmotic medium or
a histone deacetylase inhibitor similarly delays entry into
mitosis, and this delay can also be prevented by inhibiting
p38. Together, these results reveal that agents or stresses that
W
 
induce global changes in chromatin topology during G2 de-
lay entry into mitosis, independent of the ATM-mediated
DNA damage checkpoint, by activating the p38 MAPK
checkpoint. The presence of this pathway obviates the ne-
cessity of postulating the existence of multiple “chromatin
modiﬁcation” checkpoints during G2. Lastly, cells that enter
mitosis in the presence of topo II inhibitors form metaphase
spindles that are delayed in entering anaphase via the spin-
dle assembly, and not the p38, checkpoint.
 
Introduction
 
The term “antephase” was coined in the mid 20th century to
denote the period in late G2, “just before  . . .  prophase be-
comes visible,” where cells delay in response to chemical and
physical insults (Bullough and Johnson, 1951). However, in
organisms containing large chromosomes, like rat kangaroos
(PtK
 
1
 
), newts, and Indian muntjacs, prophase can last for
 
 
 
1 h. Importantly, in these cells the commitment to mitosis
does not occur until the nucleoli begin to fade, 
 
 
 
15 min be-
fore nuclear envelope breakdown (NEB; for review see Pines
and Rieder, 2001). Before NEB, chromosome condensation
can be arrested, and even reversed, by various treatments (for
review see Mikhailov and Rieder, 2002). Thus, in cells like
PtK
 
1
 
 the end of G2, or antephase, can be expanded to en-
compass the early stages of chromosome condensation.
The arrest or reversal of chromosome condensation dur-
ing prophase provides a unique visible cue that entry into
mitosis has been delayed, and we have been using this fea-
ture to study how the G2/M transition is regulated. This as-
say has a numeric readout, the duration of prophase, and
also a qualitative readout, the degree of chromatin condensa-
tion (a measure of CDK activity). In our initial studies we
found that disassembling microtubules induces a 3–4-h de-
lay in completing prophase (Rieder and Cole, 2000), a be-
havior that is likely mediated by a checkpoint involving the
Chfr protein (Scolnick and Halazonetis, 2000; Chaturvedi
et al., 2002; Matsusaka and Pines, 2004). Recently, we used
this assay to explore how inhibiting topoisomerase II (topo
II) and other enzymes involved in chromatin structure affect
the G2/M transition. The results of these studies, which are
described here, reveal that drugs which modify chromatin
topology during late G2 delay entry into mitosis, indepen-
dent of the ATM kinase, by activating the p38 MAPK
checkpoint pathway.
 
Results
 
All topo II inhibitors delay the G2/M transition. To explore
the mechanism behind this delay we treated antephase PtK
 
1
 
and Indian muntjac cells with various topo II inhibitors, and
then followed their behavior by time-lapse video light mi-
croscopy. We used a topo II poison (adriamycin) known to
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produce double-strand breaks (DSBs), as well as catalytic in-
hibitors (ICRF-193, merbarone) that are not supposed to
damage DNA. We also used aclarubicin which, by intercalat-
ing into DNA, inhibits decatenation (Perrin et al., 1998) by
preventing topo II from binding to chromatin (Kellner et al.,
2002). Not unexpectedly all of these agents delayed progres-
sion through prophase (Table I). When exposed to 4 
 
 
 
M
ICRF-193 or 1 
 
 
 
M aclarubicin the chromosomes in early to
mid prophase cells decondensed, and then slowly recon-
densed, or they continued to slowly condense over a pro-
longed prophase period (Table I; Fig. 1, A and B). When
these cells finally entered mitosis their chromosomes exhibited
the typical nondecatenated phenotype (Gorbsky, 1994), i.e.,
they were less compacted than normal and the chromatids
failed to separate during the ensuing anaphase (Fig. 1, A and
B). Adriamycin “froze” cells in a prophase-like state for 
 
 
 
10 h
(Fig. 1 C), whereas merbarone arrested the cells in antephase
after the chromosomes had decondensed (not depicted).
 
ICRF-193 and merbarone, but not aclarubicin, induce 
the formation of 
 
 
 
–H2AX complexes during antephase
 
To explore if catalytic inhibitors of topo II delay G2 in the
absence of DSBs, we used the phosphorylation of histone
H2AX on Ser
 
139
 
 (i.e., the formation of 
 
 
 
–H2AX complexes)
as a sensitive visible assay for DSB formation (Rogakou et
al., 1998; Caspari and Carr, 2002). We found that a 1-h
treatment with 4 
 
 
 
M ICRF-193 or 40 
 
 
 
M merbarone pro-
duced multiple 
 
 
 
–H2AX foci in antephase cells (Fig. 2 A),
although many fewer than adriamycin treatment. In con-
trast, treatment with aclarubicin did not produce 
 
 
 
–H2AX
foci above that of the background (Fig. 2 A), even at concen-
trations that strip topo II
 
 
 
 from chromosomes in 40 min
(Fig. 2 B). During interphase and mitosis chromatin bound
topo II
 
 
 
 is in a rapid dynamic exchange with unbound topo
II (Christensen et al., 2002; Tavormina et al., 2002). Thus,
the induction of multiple 
 
 
 
–H2AX foci by ICRF-193 and
merbarone imply (Caspari and Carr, 2002) that these drugs
induce significant DSBs in vivo
 
.
 
ATM is not involved in the antephase delay induced by 
catalytic inhibitors of topo II
 
During antephase adriamycin, ICRF-193 and merbarone ac-
tivate the ATM kinase as evident from the fact that they in-
Figure 1. Drugs that inhibit topo II delay progression through 
antephase/prophase. Early to mid-prophase PtK1 cells were located 
 30 min after adding conditioned medium containing 4  M ICRF-
193 (A), 0.75–1  M aclarubicin (B), or 10  M adriamycin (C). They 
were then followed by time-lapse DIC (A and C) or phase-
contrast (B) microscopy, to determine the duration of prophase 
and prometaphase/metaphase. Both ICRF-193 (A) and aclarubicin (B) 
significantly (4–5 ) prolong the duration of prophase, which normally 
takes  45 min at 37 C (see Tables I and II). Note that with both treat-
ments the cells ultimately form normal looking metaphase spindles 
that entered an abnormal anaphase. By contrast, cells treated with 
adriamycin (C) remained in a prophase-like state until the recordings 
were terminated. Time in hours (h) and minutes (min), since the onset 
of recording, is in the upper left corner of each image. Bars, 10  m.
 
Table I. 
 
Duration of prophase in Ptk1 cells treated with topo II 
inhibitors, stress-inducting, and DNA-damaging agents
Treatment None
Caffeine
(5–10 
 
 
 
M/4 h)
SB203580
(50 
 
 
 
M/1 h)
 
None 45 
 
 
 
 3 (25) 44 
 
 
 
 10 (9) 42 
 
 
 
 9 (4)
Adriamycin (10 
 
 
 
M)
 
 
 
600* (3)
 
 
 
600*, 
 
n
 
 
 
  
 
5 90 
 
 
 
 53 (3)
ICRF-193 (4 
 
 
 
M) 224 
 
 
 
 92 (18) 80 
 
 
 
 37 (5) 51 
 
 
 
 8 (5)
Merbarone (40 
 
 
 
M)
 
 
 
600* (5)
 
 
 
600* (2) 51 
 
 
 
 12 (3)
Aclarubicin (0.75–1 
 
 
 
M) 163 
 
 
 
 72 (18) 202 
 
 
 
 49 (4) 55 
 
 
 
 23 (7)
Anisomycin (5–7.5 ng/ml) 197 
 
 
 
 80 (6)
 
 
 
600* (4) 55 
 
 
 
 20 (5)
50 laser pulses
into nucleus
 
 
 
600* 51 
 
 
 
 7 (6)
 
 
 
*120 (5)
The duration of prophase (min) in PtK
 
1
 
 cells after disrupting chromatin
structure in the presence of ATM/ATR (caffeine, 5–10 
 
 
 
M) or p38
(SB203580, 40–50 
 
 
 
M) kinase inhibitors. In the presence of SB203580
alone, PtK
 
1
 
 cells enter mitosis and divide normally for up to 2 d (not
depicted). Adriamycin, ICRF-193, merbarone, and aclarubicin all
inhibit topo II. Anisomycin activates the p38 kinase, and laser
irradiation selectively induces DSBs in the nucleus. The asterisk
indicates that cells did not enter mitosis during the indicated time of
observation. 
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duce 
 
 
 
–H2AX foci (Fig. 2 A), which requires ATM activity
(Fernandez-Capetillo et al., 2002). Does aclarubicin, which
does not induce 
 
 
 
–H2AX foci above that of background,
similarly activate ATM? To answer this question we treated
CFPAC-1 cultures for 1 h with adriamycin or aclarubicin be-
fore preparing whole cell extracts. We then stained Western
blots of these extracts for total and activated (serine 1981-P;
Bakkenist and Kastan, 2003) ATM. As predicted from our
 
 
 
–H2AX studies, adriamycin activates the ATM kinase but
aclarubicin does not, even at high concentrations (Fig. 3 A).
Figure 2. Aclarubicin does not induce DSBs and 
depletes chromosomes of topo II. (A) ICRF-193, 
merbarone, and adriamycin induce DSBs ( –H2AX 
complexes) in prophase cells, whereas aclarubicin 
does not. CFPAC-1 cells were treated with DMSO 
(Control), 4  M ICRF-193, 40  M merbarone, 10  M 
adriamycin, or 1  M aclarubicin in conditioned 
media for 1 h. They were then fixed and stained 
as described previously for  –H2AX complexes 
(Mikhailov et al., 2002). (Left) Hoechst 33342 and 
 –H2AX antibody. (Right)  –H2AX antibody channel. 
Note that all topo II inhibitors except aclarubicin 
induce formation of  –H2AX complexes above 
that of the background. Bar, 10  m. (B) PtK1 cells 
were fixed 10, 20, 30, and 40 min after incubation 
in 1  M aclarubicin, and stained for chromatin 
(left, Hoechst 33342) and the IMF localization of 
topo II  (right). Note that aclarubicin depletes the 
chromosomes of topo II  in 30–40 min. Bars, 10  m.
 
Figure 3.
 
ATM is activated by adriamycin but not aclarubicin, and 
both topo II inhibitors activate p38.
 
 (A) CFPAC cells were grown for 
4 h in the presence of DMSO (control) or SB203580. They were then 
exposed to different concentrations of aclarubicin or adriamycin. 
Whole cell lysates were separated on 6% acrylamide gels and blotted 
for activated (pS1981) and general ATM. Note that ATM is activated 
by adriamycin, but not aclarubicin, even at high concentrations. 
(B) Hela cells enriched in S, G2 and M-phase were collected after 
release from double thymidine block. Cells were exposed to different 
concentrations of aclarubicin (ACLA) and adriamycin (ADR) for 50 
min during the G2-M transition. Whole cell lysates were then sepa-
rated on a 12% acrylamide gel and blotted for activated (T*GY*) and 
general p38. Note that p38 is activated during G2/M by adriamycin 
and aclarubicin in a dose-dependent manner. White lines indicate 
that intervening lanes have been spliced out. 
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Next, we asked if aclarubicin causes cells lacking the ATM
kinase to delay in late G2. For this experiment, we filmed
fields of human GM16666A (
 
 
 
/
 
 
 
 ATM) cell cultures in
the presence or absence of 1 
 
 
 
M aclarubicin. From these
records, we determined the percentage of cells in mitosis ev-
ery hour, over a 7-h period, as well as the number that en-
tered mitosis (underwent NEB) each hour. These data (Fig.
4) clearly reveal that aclarubicin rapidly delays the G2/M
transition in cells lacking ATM.
Because aclarubicin delays the G2/M transition in the ab-
sence of ATM activation, the delay induced by this catalytic
topo II inhibitor is not due to the DNA damage checkpoint.
To determine if this is also true for other topo II inhibitors,
we pretreated PtK
 
1
 
 cultures for 4 h with 5–10 mM caffeine
or wortmannin, potent inhibitors of the ATM kinase (Zhou
et al., 2000), before adding topo II inhibitors. We found
that caffeine or wortmannin did not prevent the antephase
delay induced by adriamycin, merbarone, or aclarubicin
(Table I). It did, however, shorten the ICRF-193 induced
delay, which is consistent with reports that ICRF-193 delays
cells in G2, at least in part via the ATM/ATR kinase (Dem-
ing et al., 2001). The inability of caffeine to override the
adriamycin-induced antephase delay may be due to the ex-
tensive DNA damage caused by this poison (Fig. 2 A),
which may trigger other pathways in addition to ATM. Re-
gardless, because caffeine does not override the antephase
delay induced by merbarone or aclarubicin, which compared
with adriamycin produce significantly fewer DSBs (Fig. 2
A), the delay must be due to pathways not involving the
ATM kinase.
 
Triggering p38 MAPK during antephase delays entry 
into mitosis
 
In addition to the ATM/DNA damage checkpoint, a caf-
feine-insensitive pathway appears to exist that delays cells in
G2 in response to UV, IR, or 
 
 
 
-irradiation (Goldstone et al.,
2001; Jha et al., 2002; Xu et al., 2002). In the case of 
 
 
 
 and
UV irradiation this arrest is mediated by the p38 MAPK
(Bulavin et al., 2001; Dmitrieva et al., 2002; for review see
Bulavin et al., 2002). This prompted us to ask if activating
p38 during antephase, with concentrations of anisomycin
(5–7 ng/ml) that do not affect protein synthesis (Bunyard et
al., 2003), delays entry into mitosis. We found that aniso-
mycin rapidly induced early to mid prophase PtK
 
1
 
 cells to
decondense their chromosomes and return to G
 
2
 
 for 
 
 
 
3 h
(Table I). Osmotic stress, which is also a potent activator of
p38 (Han et al., 1994; Dmitrieva et al., 2002), similarly
induced early to mid prophase cells to decondense their
chromosomes and delay in antephase (unpublished data).
By binding to the ATP site on p38, the small molecule
SB203580 potently and selectively inhibits the downstream
activity of p38 without preventing its activating phosphor-
ylation (Gum et al., 1998; Lisnock et al., 1998). Not un-
expectedly, if p38 activity was prevented in PtK
 
1
 
 with
SB203580, before treating antephase cells with anisomycin
(Table I) or hypertonic medium (not depicted), they entered
prometaphase with near normal kinetics. Thus, activating
p38 during antephase delays entry into mitosis, and this de-
lay can be eliminated by inhibiting p38 with SB203580.
 
Topo II inhibitors activate the p38 pathway
 
To determine if topo II inhibitors activate p38 during
G2/M we treated synchronized HeLa cells with adriamycin
or aclarubicin. Western blots of whole cell extracts, immu-
nostained for total and active p38 (T*GY*), confirm that
p38 is not normally active in HeLa during S and G2/M
(Fig. 3 B; for review see Deacon et al., 2003). However, it is
clearly activated in a dose-dependent manner when G2/M
cells are treated with adriamycin or aclarubicin (Fig. 3 B).
Thus, inhibitors of topo II, including those that produce few
if any DSBs, activate the p38 MAPK. P38 is highly con-
served and antibodies against human p38 detected p38 in
nonsynchronizable PtK
 
1
 
 cells (unpublished data). We also
found that agents known to stimulate (anisomycin) or in-
hibit (SB203580) p38 in human cells also work on marsu-
pial cells.
 
Inhibiting p38 activity overrides the antephase delay 
caused by topo II inhibitors
 
We next incubated PtK
 
1
 
 cultures in SB203580 before treat-
ing them with topo II inhibitors. We found that inhibiting
p38 with SB203580 completely abolished the antephase de-
lay seen after treating cells with ICRF-193, merbarone or
aclarubicin, and it significantly reduced the delay after adria-
Figure 4. Aclarubicin inhibits the G2/M transition in human cells 
lacking the ATM kinase. Fields of human GM16666A cells, lacking 
a functional ATM ( /  ATM) kinase, were followed by video LM for 
7 h before (top) and after exposure to 1  M aclarubicin (bottom). 
The number of cells in mitosis at the end of each hour (gray squares), 
as well as those undergoing NEB during each hour (black squares), 
were determined for each field. Error bars represent SEM. 
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mycin treatment (Table I; Fig. 5 A). During aclarubicin
treatment the cells entered mitosis with little or no chromo-
some-bound topo II (Fig. 2 B). Pre-incubating PtK
 
1
 
 cells
with SB202474, an inactive analogue of SB203580, did not
prevent the antephase delay (unpublished data). We then re-
peated these experiments with another potent p38 inhibitor,
2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-
dihydropyrazol-3-one (de Laszlo et al., 1998), and obtained
the same results (unpublished data). Finally, the Jun-N-ter-
minal (JNK) MAPK shares a high degree of structural and
functional homology with p38. To determine if JNK is in-
volved in the G2 delay induced by topo II inhibitors we in-
hibited this MAPK during prophase with 30 
 
 
 
M SP600125
(Bennett et al., 2001) and found that it did not prevent the
antephase delay (unpublished data).
We then repeated the p38 inhibitor experiments on
Indian muntjac (Table II; Fig. S1, available at http://www.
jcb.org/cgi/content/full/jcb.200405167/DC1), human
CFPAC-1, and hTERT-RPE-1 cells (Fig. 5, B and C) and
obtained similar results. The duration of visible prophase in
CFPAC-1 and RPE-1 is 
 
 
 
15 min, and by the time chromo-
some condensation is evident the cells are committed to mi-
tosis. To determine how these cells respond to inhibiting
topo II in late G2, in the presence or absence of active p38,
we used video light microscopy to follow populations for
6–8 h after drug addition. When treated only with SB203580
the cells entered and completed prophase with normal kinet-
ics for at least 7 h (Fig. 5, B and C). As with PtK1 and Indian
Figure 5. Cells treated with topo II inhibitors in late G2 enter mitosis with normal kinetics when p38 is inhibited with SB203580. (A) Sequential 
images of a SB203580 treated PtK1 cell entering mitosis in the presence of 0.75  M aclarubicin. Time in min is in top left corner of each frame. 
After NEB (50 min) this cell formed a metaphase spindle (110 min) which entered anaphase (147 min). In the presence of the p38 inhibitor, 
aclarubicin does not delay entry into mitosis although it does delay exit from mitosis. Bar, 10  m. (B and C) CFPAC-1 (B) and hTERT-RPE1 (C) 
cells were followed for 7 h as described in Materials and methods. To distinguish cells blocked in mitosis from those entering mitosis from 
late G2, the percent of cells undergoing NEB (black line) and already in mitosis (gray line) were determined for each hour. Points are average 
data for every hour post-drug addition, error bars show standard error of the average. 30  M SB203580 somewhat decreased the frequency of 
mitosis in CFPAC cells but it had no effect on hTERT-RPE1 cells.
Table II. Duration of prophase in Indian muntjac cells treated with 
topo II inhibitors
Treatment None
SB203580
(50  M/1 h)
None 55   13 (16) 49   16 (5)
Aclarubicin (0.75–1  M) 300   141 (3) 57   4 (6)
ICRF-193 (4  M) 384   187 (3) 101   35 (2)
Duration of prophase (min) in Indian muntjac cells treated with aclarubicin
or ICRF-193 in the absence or presence of SB203580. Note that inhibiting
p38 significantly reduces the duration of prophase in cells treated with topo
II inhibitors. The data in A and B represent the average   SD; the number
of cells followed is shown in parentheses.522 The Journal of Cell Biology | Volume 166, Number 4, 2004
muntjac cells, both ICRF-193 and aclarubicin rapidly inhib-
ited entry into mitosis in CFPAC-1 (Fig. 5 B) and RPE-1
(Fig. 5 C) cultures. However, the inhibition could be largely
overridden during the first several hours by first treating
the cultures with SB203580. After 4–7 h in aclarubicin,
CFPAC-1 and hTERT-RPE1 cells fail to enter mitosis even
when p38 is inhibited. This is likely due to toxic effects aris-
ing, e.g., from the inability of late S or early G2 cells in acla-
rubicin-treated cultures to transcribe genes required for cell
cycle progression.
Inhibiting histone deacetylase also delays the G2/M 
transition via p38
One interpretation of our results is that topo II inhibitors
and osmotic shock impede the G2/M transition because they
induce abnormal chromatin topology which activates the
p38 pathway. To explore whether other agents that globally
disrupt chromatin structure delay cells in antephase via p38
we treated PtK1 cells with apicidin, a potent histone deacety-
lase inhibitor (Witt et al., 2003). Because histone deacetylase
is recruited to DNA by other proteins, inhibiting its activity
during antephase with 0.5  M apicidin should not, and
does not (Fig. 6 C), induce  –H2AX foci (DSBs) above
background. However, others have shown that inhibiting
histone deacetylase alters chromatin structure (Grunstein,
1997) and arrests cell cycle progression via an undefined
checkpoint (Qiu et al., 2000). Not unexpectedly we found
that inhibiting histone deacetylase during early prophase de-
layed entry into mitosis by either inducing the chromosomes
to decondense (n   2; Fig. 6 A), or by prolonging prophase
(159   87 min; n   3). Importantly, this delay was elimi-
nated when cells were pretreated with SB203580 (52   11
min; n   3; Fig. 6 B), but not caffeine (not depicted). For
controls we treated early prophase cells with lumi-colcemid
or cytochalasin D, which do not affect chromatin structure,
and found that they entered mitosis with normal kinetics
(not depicted; for review see Rieder and Cole, 2000).
Localized DSBs delay entry into mitosis via the ATM 
and not P38 checkpoint pathway
So far our data support the idea that global disruptions in
chromatin topology delay cell cycle progression via the p38
Figure 6. Inhibiting histone deacetylase delays progression through antephase via a p38-dependent mechanism. (A) PtK1 cells treated in 
early prophase with apicidin either spend a prolonged period in prophase or, as illustrated here (top), decondense their chromosomes and return 
to antephase. (B) In contrast, when cells are exposed to the p38 inhibitor SB203580, and then apicidin, the duration of prophase is similar to 
nontreated controls ( 50 min). (C) A 1-h treatment of antephase cells with 0.5  M apicidin does not induce the formation of  –H2AX foci 
(DSBs) above that of background. Time is in minutes indicated in top left corner of each frame. Bar, 10  m.
Figure 7. Inhibiting p38 does not over-
ride the ATM/DNA damage checkpoint. 
(A) When the nucleus of early prophase 
PtK1 cells is irradiated with 50 pulses of 
laser light the chromosomes decondense 
and the cell returns to an interphase 
morphology. This response is not pre-
vented by inhibiting p38 with SB203580 
(A), but it is prevented when the ATM 
kinase is inhibited with caffeine (B). 
The cell in B was fixed after NEB and 
processed for the detection of both 
DNA (Hoechst) and DSBs ( –H2Ax). 
Bars, 10  m.Chromatin structure and the G2/M transition | Mikhailov et al. 523
pathway independent of DSBs. This model predicts that in-
ducing DSBs in just a few highly localized regions of the nu-
cleus will not arrest antephase cells via the p38 pathway. To
test this we “stitched” nuclei in antephase PtK1 cells with 50
pulses of 546-nm laser light. This produces highly localized
regions of  –H2AX foci (unpublished data; for review see
Rogakou et al., 1999) and delays antephase cells from enter-
ing mitosis (Rieder and Cole, 1998). When we repeated
these experiments after inhibiting p38 with SB203580, the
cells continued to decondense their chromosomes and were
blocked in antephase (Table I; Fig. 7 A). However, if we
pretreated cultures with 5–10 mM caffeine before stitch-
ing early prophase nuclei, the cells progressed into mitosis
with normal kinetics even though they contained numerous
DSBs (Table I; Fig. 7 B). This experiment reveals that
SB203580 does not inhibit the ATM kinase. It also demon-
strates that the localized disruption of chromatin does not
activate p38, or that if it is activated under this condition it
does not contribute to the cell cycle delay.
P38 activity is not required for progression through 
mitosis or for the spindle assembly checkpoint
Cells that enter mitosis in the presence of ICRF-193 form
metaphase spindles that are delayed in entering anaphase
(Mikhailov et al., 2002). Here, we report that aclarubicin-
treated cells, driven into mitosis by inhibiting p38, also form
spindles that are delayed in metaphase (Fig. 5 A). This was
true for all cell types tested, including PtK1 (Table III), In-
dian muntjac (Fig. S1 B), CFPAC (185   54 min, n   4 vs.
60   7 min. n   9), HeLa (160   56 min, n   56 vs. 46  
6 min, n   2), and U2OS (238   90 min, n   5 vs. 43  
14 min, n   5).
As reported by others (Deacon et al., 2003), we found that
p38 is not activated as untreated HeLa cells transit from G2
into mitosis (Fig. 3 B). Therefore, it is not surprising that in-
hibiting p38 with SB203580 had no effect on the duration
of mitosis in untreated PtK1 cells (Table III). From our live
cell studies it was also clear that the delay in mitosis caused
by aclarubicin, or disrupting microtubule assembly with no-
codazole, is not overridden by inhibiting p38 in PtK1 (Table
III) or Indian muntjac (Fig. S1 C). Under both conditions it
is, however, rapidly eliminated when the cells are injected
with a dominant negative Mad2 spindle assembly check-
point component (see Mikhailov et al., 2002; unpublished
data). Thus, p38 activation is not required for normal mi-
totic progression or for the spindle assembly checkpoint in
PtK1 or Indian muntjac cells.
Discussion
Topo II is the only enzyme that can cut and rejoin double-
strand DNA, and it is used to relieve torsional stress caused
e.g., during DNA replication, transcription and repair. The
enzyme is particularly active during the G2 and M phases of
the cell cycle where it is involved in many aspects of DNA
metabolism and chromatin topology. Two features have
made topo II a primary target for some of the most widely
prescribed antibiotics and anticancer drugs currently in clin-
ical use: it serves an indispensable function and it lacks bio-
logical redundancy (Froelich-Ammon and Osheroff, 1995;
Kellner et al., 2002). Because deleting topo II is usually le-
thal, its function is studied primarily by disrupting its activ-
ity with “poisons” that stabilize the enzyme on cleaved
DNA, or with “catalytic” inhibitors that bind the enzyme
before it cuts DNA, or after it has been rejoined.
The synthesis of topo II  starts in G1 and peaks in G2,
whereas topo II  expression is continuous throughout the
cell cycle (Kellner et al., 2002). As a result, poisons like
ICRF-193 and merbarone, that preferentially bind to and
inhibit topo II –catalyzed decatenation (Perrin et al.,
1998), delay cells selectively in G2 (Deming et al., 2002). In
contrast, by intercalating directly into chromatin aclarubicin
prevents decatenation by both topo II  and   (Perrin et al.,
1998). As a result, this drug delays progression through all
stages of the cell cycle including G2 (Teillaud et al., 1998).
The mechanism(s) by which topo II inhibitors delay cell
cycle progression are only vaguely understood. Work with
the catalytic inhibitor ICRF-193 suggested that this delay is
mediated by a caffeine-sensitive pathway that monitors chro-
matin decatenation (Downes et al., 1994; Clifford et al.,
2003). Subsequent work suggested that this “decatenation
checkpoint” delays entry into mitosis, independent of the
p53 pathway (Kaufmann et al., 2002), by using the ATR ki-
nase and BRCA1 to inhibit the polo-like kinase (Deming et
al., 2001, 2002; Kaufmann et al., 2002). The idea that a G2
“decatenation” checkpoint exists, distinct from the DNA
damage checkpoint, is based largely on indirect observations
and biochemical data that ICRF-193 does not induce DSBs.
However, recent work (Huang et al., 2001; Wang and East-
mond, 2002), as well as our own data (Fig. 2), reveals that
many of these drugs, including ICRF-193 and merbarone, do
damage DNA in vivo. Furthermore, it is now clear that the
ATR kinase implicated in the so called decatenation check-
point has considerable overlap with the ATM kinase which
arrests cells in response to DSBs (Durocher and Jackson,
2001). Finally, because sister chromatids do not become fully
decatenated until the metaphase/anaphase transition, it is dif-
ficult to envision how a checkpoint monitoring the state of
DNA catenation can delay the G2/M transition when cells
normally enter mitosis with catenated chromatids.
Topo II and histone deacetylase inhibitors delay the 
G2/M transition by activating the p38 pathway
Our data reveal that, when applied to antephase (late G2)
cells, topo II inhibitors delay entry into mitosis via the p38
Table III. Duration of mitosis
a in Ptk1 cells treated with 
nocodazole, anisomycin, or aclarubicin
Treatment None SB203580
None 50   2 (7) 57   10 (8)
Nocodazole 136   20 (13) 337   107 (5)
Anisomycin (5–7.5 ng/ml) 46   18 (6) 40   12 (5)
Aclarubicin (1.5–3  M) 128   38 (10) 158   54 (4)
The duration of mitosis (NEB to anaphase onset) in PtK1 cells treated at 37 C
with nocodazole, anisomycin, or aclarubicin, with or without prior
treatment with the p38 inhibitor SB203580. The data represents the
average   SD; number of experiments is shown in parentheses.
aNuclear envelope breakdown to anaphase onset.524 The Journal of Cell Biology | Volume 166, Number 4, 2004
MAPK, and not the ATM, pathway. Because this delay is
triggered in minutes, by a route that functions well into
prophase, it does not require activation of transcription fac-
tors (like p53) or new protein synthesis. The p38 MAPK
pathway fulfills the criteria for a checkpoint control, at least
during late G2: at this time it is normally not active and,
when activated, it delays cell cycle progression via a route
that shows a relief of dependence. Importantly, under many
conditions this delay is transient and it is ultimately by-
passed by an adaptation process, even when the problem
cannot be fixed. This control provides a mechanism during
the G2/M transition, as it appears to also do during the G1/S
transition (Kyriakis and Avruch, 2001), for quickly delaying
cell cycle progression in response to diverse stresses. In the
absence of such a rapid response system, such stresses may
well lead to chromosome segregation problems during mito-
sis independent of those generated by DNA damage. The
p38 checkpoint pathway thus gives the cell time to recover,
just before important transitional events, in cases where the
insult is transient. If need be, it also allows other checkpoints
that require transcription time to work.
What does the “topo II checkpoint” monitor if not chro-
matin decatenation? Topo II inhibitors either bind to chro-
matin (aclarubicin) or lock the enzyme on chromatin in an
inactive form (adriamycin, ICRF-193, merbarone). One
possibility is that as these drugs bind, they induce a global
change in chromatin topology that delays the G2/M transi-
tion by activating the p38 pathway. This idea is supported
by our data, and those of others, that osmotic shock and his-
tone deacetylase inhibitors, which similarly induce global
changes in chromatin topology, also delay the G2/M transi-
tion via the p38 pathway. It is also consistent with our find-
ing that selectively damaging chromatin in just a few regions
of the antephase nucleus delays entry into mitosis via the
ATM and not p38 kinase pathway.
How could global changes in chromatin topology during
antephase activate p38? One possibility is that regions of
chromatin bind an unidentified factor that is released in re-
sponse to abnormal chromatin topology. Once released this
factor may interact with c-Abl and/or DNA-protein kinase
(Kharbanda et al., 1997) to initiate a kinase cascade (Bran-
cho et al., 2003) that activates p38. Active p38 can influence
cell behavior by activating transcription factors or other ki-
nases. Because the antephase response we describe is rapid,
and occurs as chromosomes are condensing, it is not due to
transcription factors like p53. Rather, the activation of p38
by abnormal chromatin topology likely initiates another
kinase cascade, perhaps involving MNK1 (Fukunaga and
Hunter, 1997), that produces the cell cycle delay. P38 can
also directly interact with Cdc25B (Bulavin et al., 2001).
The antephase checkpoint may work by ultimately blocking
activation of cyclin A/CDK2 via Cdc25, which in response
can occur independent of ATM/ATR (Goldstone et al.,
2001; Mitra and Enders, 2004).
We find that the delay in entering mitosis induced in late
G2 cells by topo II inhibitors is caffeine insensitive and does
not involve the ATM kinase. Bakkenist and Kastan (2003)
report that based primarily on immunofluorescence (IMF)
data, osmotic stress, and histone deacetylase inhibitors in-
duce a diffuse phosphorylation of ATM in the absence of
DSBs. This suggested that ATM is activated globally by
changes in chromatin structure, and then later accumulates
at DSBs when present. Our results reveal that these same
treatments delay the G2/M transition. However, we find
that this delay is not overridden by inhibiting ATM with
caffeine or wortmannin (or in  /  ATM cells), yet it is
eliminated by preventing p38 kinase activity. We also find
that topo II inhibitors which induce DSBs activate both
ATM (as evidenced by  –H2AX foci formation) and p38,
but that inhibitors that do not induce DSBs (aclarubicin) do
not activate ATM. Regardless, with the exception of adria-
mycin, which induces massive numbers of DSBs, all of these
inhibitors delay entry into mitosis via the p38 and not ATM
pathway. These results imply that, by itself, the global acti-
vation of ATM by changes in chromatin topology does not
produce a late G2 delay independent of the p38 pathway.
P38 activity is not required for entry into mitosis or the 
spindle assembly checkpoint
The spindle assembly checkpoint delays anaphase when ki-
netochores are not stably associated with the spindle. Work
on 3T3 and HeLa cell populations suggests that p38 is acti-
vated in response to spindle poisons (Deacon et al., 2003),
and that this activity is required for the spindle assembly
checkpoint (Takenaka et al., 1998). However, in situ studies
conclude that p38 is normally active during mitosis, and that
this activity is required to overcome this checkpoint (Campos
et al., 2002). Cell sorting studies even suggest that inhibiting
p38 does not influence the mitotic arrest or slippage of HeLa
cells treated with nocodazole (Tsuiki et al., 2001).
As reported by others (Deacon et al., 2003) we found that
p38 is not activated as untreated HeLa cells transit from G2
into mitosis (Fig. 3 B). We also found that inhibiting p38
does not influence the rate at which CFPAC-1 or hTERT-
RPE1 cells enter mitosis (Fig. 5, B and C), or the duration
of the mitotic delay induced in live PtK1 or Indian muntjac
cells by nocodazole or topo II inhibitors. This latter delay is,
however, rapidly abrogated when cells are injected with a
dominant negative construct of Mad2 (Mikhailov et al.,
2002). From these observations we conclude that p38 activ-
ity is neither required for entry into mitosis, for normal mi-
totic progression, or for the spindle assembly checkpoint in
PtK1 or Indian muntjac cells.
Many of the chemical or physical insults that delay the
G2/M transition also delay the metaphase/anaphase transi-
tion. With few exceptions, most of these globally perturb
chromatin topology. Good examples here include chromatin
damage caused by radiation (Mikhailov et al., 2002), and in-
hibitors of topo II (Illidge et al., 2000; Mikhailov et al.,
2002) or histone deacetylase (Cimini et al., 2003). We pro-
pose that topo II and histone deacetylase inhibitors delay en-
try into and exit from mitosis because they bind to and in-
duce structural changes in chromatin. During antephase
these changes are detected by the p38 pathway. During mi-
tosis they impede satisfaction of the spindle assembly check-
point by deleteriously affecting kinetochore structure and
thus their stable attachment to the spindle.
Finally, we found that cells arrested in G2 by drugs that
prevent normal topo II function can be driven into a highly
aberrant mitosis by simply overriding activation of the P38Chromatin structure and the G2/M transition | Mikhailov et al. 525
MAPK. Many of these drugs are currently used as a primary
or adjunct chemotherapy in cancer treatment (Froelich-
Ammon and Osheroff, 1995; Kellner et al., 2002). One in-
teresting avenue may therefore be to explore the clinical ef-
fects of combining topo II and p38 inhibitors.
Materials and methods
Cell culture
PtK1, HeLa, U2OS, CFPAC-1, and hTERT-RPE1 were cultured on coverslips
as detailed previously (Mikhailov et al., 2002). Indian muntjac cells were
grown in DME supplemented with 10% FBS. GM1666A cells were grown
on coverslips in DME supplemented with 10% FBS and 100  g/ml hygro-
mycin; 12 h before the experiment cells were placed in hygromycin-free
media.
Coverslip cultures of PtK1 and Indian muntjac cells were assembled into
Rose chambers (Khodjakov and Rieder, 2004) at least 5 h before the start
of each experiment, whereas those containing CFPAC, hTERT-RPE, and
GM16666A cells at least 12 h before each experiment. Once assembled
the Rose chambers were then incubated at 37 C.
Reagents
Adriamycin and caffeine were purchased from Sigma-Aldrich. Merbarone
(5-(N-phenylcarboxamido)-2-thiobarbituric acid), aclarubicin (Aclacino-
mycin A), SB203580, SB 202474, JNK Inhibitor II (SP600125), apicidin,
and 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyra-
zol-3-one were purchased from Calbiochem. ICRF-193 was a gift from A.
Creighton (St. Bartholomew’s Hospital College, London, UK). In all in-
stances, reagents were added to conditioned media before use.
Western blotting
Cells were washed in ice-cold PBS and scraped from the culture into cold
buffer containing 20 mM Hepes, pH 7.4, 2 mM EGTA, 50 mM  -glycero-
phosphate, 2 mM EDTA, 137.5 mM NaCl, 10% glycerol, 1 mM DTT, 1
mM Na3VO4, 40  M PMSF, 1% Triton X-100, and complete protease in-
hibitor cocktail (Roche Diagnostics Corp.). After 10 min on ice, the lysate
was centrifuged at 14,000 rpm (4 C) for 10 min and the supernatant was
used as whole cell extract. Equal amounts of protein were separated on re-
ducing SDS-PAGE gels, immunoblotted and detected by ECL. To assay for
general and active (T
180GY-phosphorylated) p38, we used antibodies from
Cell Signaling Technology, Inc. and Promega Biosciences, Inc. General
and S
1981-phosphorylated ATM was detected with antibodies from Cell Sig-
naling (“5C2”) and Rockland, Inc., correspondingly.
Immunochemical techniques
Rabbit antibody to human topo II was purchased from TopoGEN. Cells
were fixed and stained for IMF, including  –H2AX, as detailed previously
(Mikhailov et al., 2002).
Laser irradiation and live cell video microscopy
Laser irradiation of early prophase nuclei was conducted with pulses of
532 nm light (Rieder and Cole, 1998). Nuclei were irradiated with 50
pulses as they were translated in a linear fashion through the fixed laser
beam. Each pulse contained  400 2 nJ of power as measured in the plane
of the specimen.
All recordings were made on microscopes housed in a 37 C
warm room, or inside custom built thermostatically regulated Plexiglas
incubators.
For mitotic index studies coverslips of CFPAC-1 and hTERT-RPE1 cells
were used at  70% confluence. For long-term recordings, Rose chambers
were mounted on the stage of Nikon Diaphot or TMS microscopes housed
in a 37 C warm room. Fields of cells were time lapsed with a 20  phase
contrast objective, and one image was acquired every 10 min for 6–10 h
using Image Pro Plus (Media Cybernetics) or Scion Image (Scion Corp.).
Sequential images were then assembled into movie stacks which were
then visually analyzed, during each hour of recording, for: (a) the total
number of cells within the field of view (usually 200–250); (b) the number
of cells entering mitosis (i.e., undergoing NEB); and (c) the total number of
mitotic cells.
Online supplemental material
One supplemental figure is included which illustrates that topo II inhibitors
delay the G2/M transition in Indian muntjac cells via a p38-dependent
mechanism. Online supplemental material is available at http://www.
jcb.org/cgi/content/full/jcb.200405167/DC1.
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